erlotinib hydrochloride has been researched along with Hormone-Dependent Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adkins, TB; Arteaga, CL; Calvo, B; Frierson, KE; Granja, Nde M; Grau, AM; Guix, M; Kelley, MC; Krontiras, H; Krop, IE; Mayer, IA; Meszoely, I; Muthuswamy, S; Pestano, G; Sanchez, V; Sanders, ME; Shyr, Y; Wieman, BM | 1 |
| Haddad, TC; Yee, D | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
1 trial(s) available for erlotinib hydrochloride and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Tandem Mass Spectrometry; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
2 other study(ies) available for erlotinib hydrochloride and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Of mice and (wo)men: is this any way to test a new drug?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Ki-67 Antigen; Mice; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2008 |
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |